A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection

Blood

Volumn 124, Issue 1, 2014, Pages 111-120

  Saleh, Rosine ^a   Wedeh, Ghaith ^a,b   Herrmann, Harald ^b   Bibi, Siham ^a   Cerny Reiterer, Sabine ^b   Sadovnik, Irina ^b   Blatt, Katharina ^b   Hadzijusufovic, Emir ^b,c   Jeanningros, Sylvie ^a   Blanc, Catherine ^d   Legarff Tavernier, Magali ^d   Chapiro, Elise ^d   Nguyen Khac, Florence ^d   Subra, Frédéric ^a   Bonnemye, Patrick ^d   Dubreuil, Patrice ^e,f,g   Desplat, Vanessa ^h   Merle Béral, Hélène ^d   Willmann, Michael ^c   Rülicke, Thomas ^c   Valent, Peter ^b   Arock, Michel ^a,d   more..

^a Ecole Normale Superieure de Cachan   (France)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e AIX MARSEILLE UNIVERSITY   (France)

^f AIX MARSEILLE UNIVERSITY   (France)

^g CNRS   (France)

^h UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 1; CD32 ANTIGEN; DASATINIB; FC EPSILON RECEPTOR IA PROTEIN; FC RECEPTOR; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HERMES ANTIGEN; IMATINIB; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN E RECEPTOR; INTERCELLULAR ADHESION MOLECULE 3; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 9; MIDOSTAURIN; ONCOPROTEIN; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; IMMUNOGLOBULIN E;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASOPHIL; CARCINOGENESIS; CELL ACTIVATION; CONTROLLED STUDY; DRUG SENSITIVITY; GENE CONVERSION; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSFECTION; HISTAMINE RELEASE; HUMAN; HUMAN CELL; MAST CELL; MASTOCYTOSIS; MEDIATOR RELEASE; MOUSE; NONHUMAN; ONCOGENE C KIT; PRIORITY JOURNAL; ROSA KIT D816V CELL LINE; ROSA KIT WT CELL LINE; SIGNAL TRANSDUCTION; SYSTEMIC MASTOCYTOSIS; XENOTRANSPLANTATION; ANIMAL; CELL LINE; CELL SEPARATION; CYTOLOGY; FLOW CYTOMETRY; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOLOGY; SCID MOUSE; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; BLOTTING, WESTERN; CELL LINE; CELL SEPARATION; FLOW CYTOMETRY; HETEROGRAFTS; HUMANS; IMMUNOGLOBULIN E; MAST CELLS; MASTOCYTOSIS, SYSTEMIC; MICE; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, SCID; PROTO-ONCOGENE PROTEINS C-KIT; TRANSFECTION;

EID: 84904004483     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-10-534685     Document Type: Article

References (62)

1. Metcalfe DD. Mast cells and mastocytosis. Blood. 2008;112(4):946-956.
2. Irani AA, Schechter NM, Craig SS, DeBlois G, Schwartz LB. Two types of human mast cells that have distinct neutral protease compositions. Proc Natl Acad Sci USA. 1986;83(12):4464-4468. (Pubitemid 16057069)
3. Moon TC, St Laurent CD, Morris KE, et al. Advances in mast cell biology: new understanding of heterogeneity and function. Mucosal Immunol. 2010;3(2):111-128.
4. Miller JS, Schwartz LB. Human mast cell proteases and mast cell heterogeneity. Curr Opin Immunol. 1989;1(4):637-642.
5. Krishnaswamy G, Kelley J, Johnson D, et al. The human mast cell: functions in physiology and disease. Front Biosci. 2001;6:D1109-D1127.
6. Vliagoftis H, Befus AD. Rapidly changing perspectives about mast cells at mucosal surfaces. Immunol Rev. 2005;206:190-203. (Pubitemid 41105171)
7. Schwartz LB. Analysis of MC(T) and MC(TC) mast cells in tissue. Methods Mol Biol. 2006;315:53-62.
8. Valent P. The riddle of the mast cell: kit(CD117)- ligand as the missing link? Immunol Today. 1994; 15(3):111-114.
9. Galli SJ, Tsai M, Wershil BK, Tam SY, Costa JJ. Regulation of mouse and human mast cell development, survival and function by stem cell factor, the ligand for the c-kit receptor. Int Arch Allergy Immunol. 1995;107(1-3):51-53.
10. Jamur MC, Oliver C. Origin, maturation and recruitment of mast cell precursors. Front Biosci (Schol Ed). 2011;3:1390-1406[Schol Ed].
11. Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. Nature. 2008;454(7203): 445-454.
12. Brown JM, Wilson TM, Metcalfe DD. The mast cell and allergic diseases: role in pathogenesis and implications for therapy. Clin Exp Allergy. 2008; 38(1):4-18. (Pubitemid 350233400)
13. Gilfillan AM, Beaven MA. Regulation of mast cell responses in health and disease. Crit Rev Immunol. 2011;31(6):475-529.
14. Galli SJ, Maurer M, Lantz CS. Mast cells as sentinels of innate immunity. Curr Opin Immunol. 1999;11(1):53-59. (Pubitemid 29082337)
15. Galli SJ, Wedemeyer J, Tsai M. Analyzing the roles of mast cells and basophils in host defense and other biological responses. Int J Hematol. 2002;75(4):363-369. (Pubitemid 43020292)
16. Galli SJ, Kalesnikoff J, Grimbaldeston MA, Piliponsky AM, Williams CM, Tsai M. Mast cells as "tunable" effector and immunoregulatory cells: recent advances. Annu Rev Immunol. 2005;23: 749-786. (Pubitemid 40563184)
17. Galli SJ, Grimbaldeston M, Tsai M. Immunomodulatory mast cells: negative, as well as positive, regulators of immunity. Nat Rev Immunol. 2008;8(6):478-486. (Pubitemid 351733419)
18. Valent P, Horny HP, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res. 2001;25(7): 603-625. (Pubitemid 32506768)
19. Valent P, Akin C, Sperr WR, et al. Mastocytosis: pathology, genetics, and current options for therapy. Leuk Lymphoma. 2005;46(1):35-48.
20. Horny HP. Mastocytosis: an unusual clonal disorder of bone marrow-derived hematopoietic progenitor cells. Am J Clin Pathol. 2009;132(3): 438-447.
21. George TI, Horny HP. Systemic mastocytosis. Hematol Oncol Clin North Am. 2011;25(5): 1067-1083, vii. [vii.].
22. Valent P, Akin C, Arock M, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol. 2012;157(3):215-225.
23. Valent P. Systemic mastocytosis. Cancer Treat Res. 2008;142:399-419.
24. Greenhawt M, Akin C. Mastocytosis and allergy. Curr Opin Allergy Clin Immunol. 2007;7(5): 387-392. (Pubitemid 47415281)
25. González-de-Olano D, Alvarez-Twose I, Vega A, Orfao A, Escribano L. Venom immunotherapy in patients with mastocytosis and hymenoptera venom anaphylaxis. Immunotherapy. 2011;3(5): 637-651.
26. Alvarez-Twose I, Bonadonna P, Matito A, et al. Systemic mastocytosis as a risk factor for severe Hymenoptera sting-induced anaphylaxis. J Allergy Clin Immunol. 2013;131(2):614-615.
27. Arock M, Le Nours A, Malbec O, Daëron M. Ex vivo and in vitro primary mast cells. Methods Mol Biol. 2008;415:241-254.
28. Butterfield JH, Weiler D, Dewald G, Gleich GJ. Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk Res. 1988; 12(4):345-355.
29. Kirshenbaum AS, Akin C, Wu Y, et al. Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/ leukemia; activation following aggregation of FcepsilonRI or FcgammaRI. Leuk Res. 2003; 27(8):677-682. (Pubitemid 36683255)
30. Laidlaw TM, Steinke JW, Tiñana AM, et al. Characterization of a novel human mast cell line that responds to stem cell factor and expresses functional FceRI. J Allergy Clin Immunol. 2011; 127(3):815-822.
31. Bodemer C, Hermine O, Palmérini F, et al. Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol. 2010;130(3): 804-815.
32. Dvorak AM. Procedural guide to specimen handling for the ultra-structural pathology service laboratory. J Electron Microsc Tech. 1987;6(3): 255-301. (Pubitemid 17096397)
33. Sperr WR, Bankl HC, Mundigler G, et al. The human cardiac mast cell: localization, isolation, phenotype, and functional characterization. Blood. 1994;84(11):3876-3884. (Pubitemid 24362488)
34. Schwartz LB, Austen KF, Wasserman SI. Immunologic release of beta-hexosaminidase and beta-glucuronidase from purified rat serosal mast cells. J Immunol. 1979;123(4):1445-1450. (Pubitemid 10220721)
35. Kuehn HS, Radinger M, Gilfillan AM. Measuring mast cell mediator release. Curr Protoc Immunol. 2010;Chapter 7:Unit7.38.
36. Valent P, Besemer J, Muhm M, Majdic O, Lechner K, Bettelheim P. Interleukin 3 activates human blood basophils via highaffinity binding sites. Proc Natl Acad Sci USA. 1989;86(14):5542-5546. (Pubitemid 19185580)
37. Herrmann H, Kneidinger M, Cerny-Reiterer S, et al. The Hsp32 inhibitors SMA-ZnPP and PEG-ZnPP exert major growth-inhibitory effects on D341/CD381 and CD341/CD38- AML progenitor cells. Curr Cancer Drug Targets. 2012; 12(1):51-63.
38. Arock M, Valent P. Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives. Expert Rev Hematol. 2010;3(4):497-516.
39. Andersen HB, Holm M, Hetland TE, et al. Comparison of short term in vitro cultured human mast cells from different progenitors - Peripheral blood-derived progenitors generate highly mature and functional mast cells. J Immunol Methods. 2008;336(2):166-174.
40. Hauswirth AW, Florian S, Schernthaner GH, et al. Expression of cell surface antigens on mast cells: mast cell phenotyping. Methods Mol Biol. 2006; 315:77-90.
41. Hauswirth AW, Escribano L, Prados A, et al. CD203c is overexpressed on neoplastic mast cells in systemic mastocytosis and is upregulated upon IgE receptor cross-linking. Int J Immunopathol Pharmacol. 2008;21(4): 797-806.
42. Royer B, Varadaradjalou S, Saas P, Guillosson JJ, Kantelip JP, Arock M. Inhibition of IgE-induced activation of human mast cells by IL-10. Clin Exp Allergy. 2001;31(5):694-704. (Pubitemid 32823813)
43. Gleixner KV, Mayerhofer M, Sonneck K, et al. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816Vmutated oncogenic variant of KIT. Haematologica. 2007;92(11):1451-1459. (Pubitemid 350144119)
44. Horny HP, Sotlar K, Valent P. Mastocytosis: state of the art. Pathobiology. 2007;74(2):121-132. (Pubitemid 46985284)
45. Yoshikubo T, Inoue T, Noguchi M, Okabe H. Differentiation and maintenance of mast cells from CD34(1) human cord blood cells. Exp Hematol. 2006;34(3):320-329.
46. Zappulla JP, Dubreuil P, Desbois S, et al. Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation. J Exp Med. 2005;202(12):1635-1641. (Pubitemid 41815869)
47. Harir N, Boudot C, Friedbichler K, et al. Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade. Blood. 2008;112(6): 2463-2473.
48. Sundström M, Vliagoftis H, Karlberg P, et al. Functional and phenotypic studies of two variants of a human mast cell line with a distinct set of mutations in the c-kit proto-oncogene. Immunology. 2003;108(1):89-97. (Pubitemid 36110869)
49. Ito T, Smr?z D, Jung MY, et al. Stem cell factor programs the mast cell activation phenotype. J Immunol. 2012;188(11):5428-5437.
50. Hundley TR, Gilfillan AM, Tkaczyk C, Andrade MV, Metcalfe DD, Beaven MA. Kit and FcepsilonRI mediate unique and convergent signals for release of inflammatory mediators from human mast cells. Blood. 2004;104(8): 2410-2417. (Pubitemid 39331841)
51. Brockow K, Metcalfe DD. Mastocytosis. Chem Immunol Allergy. 2010;95:110-124.
52. Ma P, Mali RS, Munugalavadla V, et al. The PI3K pathway drives the maturation of mast cells via microphthalmia transcription factor. Blood. 2011; 118(13):3459-3469.
53. Casteran N, De Sepulveda P, Beslu N, et al. Signal transduction by several KIT juxtamembrane domain mutations. Oncogene. 2003;22(30):4710-4722. (Pubitemid 36976446)
54. Chaix A, Lopez S, Voisset E, Gros L, Dubreuil P, De Sepulveda P. Mechanisms of STAT protein activation by oncogenic KIT mutants in neoplastic mast cells. J Biol Chem. 2011;286(8): 5956-5966.
55. Baumgartner C, Cerny-Reiterer S, Sonneck K, et al. Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein KIT D816V. Am J Pathol. 2009; 175(6):2416-2429.
56. Mayerhofer M, Gleixner KV, Hoelbl A, et al. Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens. J Immunol. 2008; 180(8):5466-5476.
57. Akin C, Brockow K, D'Ambrosio C, et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol. 2003;31(8):686-692. (Pubitemid 36945381)
58. Hoffmann KM, Moser A, Lohse P, et al. Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2-year-old boy carrying a somatic KIT mutation. Blood. 2008; 112(5):1655-1657.
59. Shah NP, Lee FY, Luo R, Jiang Y, Donker M, Akin C. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood. 2006;108(1):286-291. (Pubitemid 43990640)
60. Growney JD, Clark JJ, Adelsperger J, et al. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood. 2005;106(2): 721-724. (Pubitemid 40981272)
61. Gerbaulet A, Wickenhauser C, Scholten J, et al. Mast cell hyperplasia, B-cell malignancy, and intestinal inflammation in mice with conditional expression of a constitutively active kit. Blood. 2011;117(6):2012-2021.
62. Valent P, Akin C, Escribano L, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest. 2007;37(6): 435-453. (Pubitemid 46817344)